10-Q 1 icui0331201510-q.htm 10-Q ICUI 03.31.2015 10-Q

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the quarterly period ended: March 31, 2015
 Or
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from:              to
 
Commission File No.: 0-19974
 ICU MEDICAL, INC.
(Exact name of Registrant as specified in its charter)
 
Delaware
 
33-0022692
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)
951 Calle Amanecer, San Clemente, California
 
92673
(Address of principal executive offices)
 
(Zip Code)
 (949) 366-2183
(Registrant’s telephone number including area code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x  No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):
 
Large accelerated filer x
 
Accelerated filer o
 
 
 
Non-accelerated filer o
 
Smaller reporting company o
(Do not check if a smaller reporting company)
 
 
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
 
Class
 
Outstanding at April 21, 2015
Common
 
15,777,942
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):  Yes o No x
 


ICU Medical, Inc.

Index

Part I - Financial Information
 
Page Number
 
 
 
Item 1. Financial Statements (Unaudited)
 
 
 
 
 
Condensed Consolidated Balance Sheets, at March 31, 2015 and December 31, 2014
 
 
 
 
Condensed Consolidated Statements of Income for the three months ended March 31, 2015 and 2014
 
 
 
 
Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2015 and 2014
 
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2015 and 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


2

PART I - FINANCIAL INFORMATION
Item1.
Financial Statements (Unaudited)

ICU Medical, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Amounts in thousands, except per share data)
 
 
March 31,
2015
 
December 31,
2014
 
(unaudited)
 
(1)
ASSETS
 
 
 
CURRENT ASSETS:
 

 
 

Cash and cash equivalents
$
308,533

 
$
275,812

Investment securities
46,254

 
70,952

Cash, cash equivalents and investment securities
354,787

 
346,764

Accounts receivable, net of allowance for doubtful accounts of $1,046 at March 31, 2015 and $1,127 at December 31, 2014
42,595

 
39,051

Inventories
37,660

 
36,933

Prepaid income taxes
4,941

 
3,963

Prepaid expenses and other current assets
6,634

 
5,818

Deferred income taxes
7,393

 
4,683

Total current assets
454,010

 
437,212

 
 
 
 
PROPERTY AND EQUIPMENT, net
82,288

 
86,091

GOODWILL
1,478

 
1,478

INTANGIBLE ASSETS, net
6,657

 
7,063

DEFERRED INCOME TAXES
9,911

 
9,258

 
$
554,344

 
$
541,102

LIABILITIES AND STOCKHOLDERS’ EQUITY
 

 
 

CURRENT LIABILITIES:
 

 
 

Accounts payable
$
12,548

 
$
11,378

Accrued liabilities
20,349

 
17,350

Total current liabilities
32,897

 
28,728

 
 
 
 
DEFERRED INCOME TAXES
2,123

 
1,376

INCOME TAX LIABILITY
1,222

 
2,746

COMMITMENTS AND CONTINGENCIES
—

 
—

STOCKHOLDERS’ EQUITY:
 

 
 

Convertible preferred stock, $1.00 par value Authorized—500 shares; Issued and outstanding— none
—

 
—

Common stock, $0.10 par value — Authorized, 80,000 shares; Issued, 15,778 shares at March 31, 2015 and 15,595 shares at December 31, 2014; Outstanding, 15,769 shares March 31, 2015 and 15,595 shares at December 31, 2014
1,578

 
1,559

Additional paid-in capital
118,367

 
107,336

Treasury stock, at cost — 9 shares at March 31, 2015 and 0 shares at December 31, 2014
(795
)
 
—

Retained earnings
418,597

 
408,911

Accumulated other comprehensive loss
(19,645
)
 
(9,554
)
Total stockholders’ equity
518,102

 
508,252

 
$
554,344

 
$
541,102

______________________________________________________
(1) December 31, 2014 balances were derived from audited consolidated financial statements.
The accompanying notes are an integral part of these condensed consolidated financial statements.

3

ICU Medical, Inc. and Subsidiaries
Condensed Consolidated Statements of Income
(Amounts in thousands, except per share data)
(unaudited)
 
 
Three months ended March 31,
 
2015
 
2014
REVENUES:
 

 
 

Net sales
$
81,323

 
$
73,113

Other
161

 
117

TOTAL REVENUE
81,484

 
73,230

COST OF GOODS SOLD
38,970

 
37,203

Gross profit
42,514

 
36,027

OPERATING EXPENSES:
 

 
 

Selling, general and administrative
20,174

 
22,519

Research and development
4,308

 
3,631

Legal settlement
7,059

 
—

Total operating expenses
31,541

 
26,150

Income from operations
10,973

 
9,877

OTHER INCOME
526

 
210

Income before income taxes
11,499

 
10,087

PROVISION FOR INCOME TAXES
(1,813
)
 
(3,430
)
NET INCOME
$
9,686

 
$
6,657

NET INCOME PER SHARE
 

 
 

Basic
$
0.62

 
$
0.44

Diluted
$
0.60

 
$
0.43

WEIGHTED AVERAGE NUMBER OF SHARES
 

 
 

Basic
15,693

 
15,097

Diluted
16,234

 
15,395

 
The accompanying notes are an integral part of these condensed consolidated financial statements.

4

ICU Medical, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income (Loss)
(Amounts in thousands)
(unaudited)
 
 
Three months ended March 31,
 
2015

2014
Net income
$
9,686

 
$
6,657

Other comprehensive loss, net of tax of $(2,720) and $(21) for the three months ended March 31, 2015 and 2014, respectively:
 

 
 

Foreign currency translation adjustment
(10,091
)
 
(76
)
Comprehensive income (loss)
$
(405
)
 
$
6,581

 
The accompanying notes are an integral part of these condensed consolidated financial statements.


5

ICU Medical, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
(unaudited)
 
 
Three months ended March 31,
 
2015
 
2014
CASH FLOWS FROM OPERATING ACTIVITIES:
 

 
 

Net income
$
9,686

 
$
6,657

Adjustments to reconcile net income to net cash provided by operating activities:
 

 
 
Depreciation and amortization
4,629

 
4,765

Provision for doubtful accounts
—

 
3

Provision for warranty and returns
31

 
(410
)
Stock compensation
2,813

 
1,973

Loss (gain) on disposal of property and equipment
2

 
(5
)
Bond premium amortization
943

 
601

Cash provided (used) by changes in operating assets and liabilities
 

 
 
Accounts receivable
(4,947
)
 
2,416

Inventories
(1,785
)
 
(2,267
)
Prepaid expenses and other assets
(980
)
 
(800
)
Accounts payable
1,951

 
382

Accrued liabilities
3,300

 
(2,557
)
Income taxes, including excess tax benefits and deferred income taxes
(2,392
)
 
1,956

Net cash provided by operating activities
13,251

 
12,714

CASH FLOWS FROM INVESTING ACTIVITIES:
 

 
 

Purchases of property and equipment
(2,357
)
 
(5,908
)
Proceeds from sale of asset
—

 
5

Intangible asset additions
(208
)
 
(120
)
Purchases of investment securities
(9,205
)
 
(36,908
)
Proceeds from sale of investment securities
31,785

 
30,936

Net cash provided (used) by investing activities
20,015

 
(11,995
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 

 
 

Proceeds from exercise of stock options
4,777

 
4,202

Proceeds from employee stock purchase plan
1,041

 
1,384

Tax benefits from exercise of stock options
3,059

 
1,178

Purchase of treasury stock
(1,435
)
 
(5,835
)
Net cash provided by financing activities
7,442

 
929

Effect of exchange rate changes on cash
(7,987
)
 
(47
)
NET INCREASE IN CASH AND CASH EQUIVALENTS
32,721

 
1,601

CASH AND CASH EQUIVALENTS, beginning of period
275,812

 
226,022

CASH AND CASH EQUIVALENTS, end of period
$
308,533

 
$
227,623

 
 
 
 
NON-CASH INVESTING ACTIVITIES
 
 
 
  Accrued liabilities for property and equipment
$
144

 
$
1,008

 
The accompanying notes are an integral part of these condensed consolidated financial statements.

6

ICU Medical, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
March 31, 2015 and 2014
(Amounts in tables in thousands, except per share data)
(unaudited)
 
Note 1:
Basis of Presentation
 
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments, consisting of only normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the consolidated results for the interim periods presented. Results for the interim period are not necessarily indicative of results for the full year. Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K of ICU Medical, Inc., a Delaware corporation, filed with the SEC for the year ended December 31, 2014.
 
We operate in one business segment engaged in the development, manufacturing and sale of innovative medical devices used in infusion therapy, oncology and critical care applications.  Our devices are sold directly or to distributors and medical product manufacturers throughout the United States and internationally.  All subsidiaries are wholly owned and are included in the consolidated financial statements.  All intercompany balances and transactions have been eliminated.

Note 2:
Legal Settlement

On April 2, 2015, an arbitrator ruled on a breach of contract claim between us and Hospira Inc., awarding Hospira $8.2 million Canadian dollars ($6.5 million U.S. dollars). The arbitrator also ruled that we shall pay 75% of Hospira's legal fees and expenses, which we estimated to be $0.8 million Canadian dollars ($0.6 million U.S. dollars). We recorded an accrual for $7.1 million on March 31, 2015.

Note 3:
New Accounting Pronouncements
 
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09.  If these proposed changes are finalized, this standard would require public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption would be permitted as of the original effective date in ASU 2014-09. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures.

In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. This

7

guidance will become effective for us at the beginning of the first quarter of 2016. We do not anticipate a material impact on our consolidated financial statements from adoption of this ASU.

Note 4:
Fair Value Measurement
 
Our investment securities consist of certificates of deposit, corporate bonds, commercial paper and federal tax-exempt state and municipal government debt. All investment securities are considered available-for-sale and are “investment grade”, carried at fair value, and there have been no gains or losses on their disposal. As of March 31, 2015, we had $3.5 million of our investment securities as Level 1 assets, which are certificates of deposit with quoted prices in active markets, and $42.8 million of our investment securities as Level 2 assets, which are pre-refunded municipal securities, non-pre-refunded municipal securities, corporate bonds and commercial paper and have observable market based inputs such as quoted prices, interest rates and yield curves. The following table provides the assets and liabilities carried at fair value measured on a recurring basis.

 
Fair value measurements at March 31, 2015 using
 
Total carrying
value
 
Quoted prices
in active
markets for
identical
assets (level 1)
 
Significant
other
observable
inputs (level 2)
 
Significant
unobservable
inputs (level 3)
Available for sale securities
$
46,254

 
$
3,484

 
$
42,770

 
$
—

 
$
46,254

 
$
3,484

 
$
42,770

 
$
—

 
 
 
Fair value measurements at December 31, 2014 using
 
Total carrying
value
 
Quoted prices
in active
markets for
identical
assets (level 1)
 
Significant
other
observable
inputs (level 2)
 
Significant
unobservable
inputs (level 3)
Available for sale securities
$
70,952

 
$
5,884

 
$
65,068

 
$
—

 
$
70,952

 
$
5,884

 
$
65,068

 
$
—

 


Note 5: Investment Securities

Our investment securities consist of certificates of deposit, corporate bonds, commercial paper and federal tax-exempt state and municipal government debt. All investment securities are considered available-for-sale and are “investment grade”, carried at fair value, and there have been no gains or losses on their disposal. Unrealized gains and losses on available-for-sale securities, net of tax, are included in accumulated other comprehensive loss in the stockholders' equity section of our consolidated balance sheets. We had no gross unrealized gains or losses on available-for-sale securities at March 31, 2015 or December 31, 2014. The scheduled maturities of the debt securities are between 2015 and 2045 and are all callable within one year. The investment securities consist of the following at March 31, 2015 and December 31, 2014:
 
March 31, 2015
 
December 31, 2014
Federal tax-exempt debt securities
$
13,760

 
$
15,013

Corporate bonds
24,513

 
46,209

Commercial paper
4,497

 
3,846

Certificates of deposit
3,484

 
5,884

 
$
46,254

 
$
70,952


    

8

Note 6: Inventories
 
Inventories consisted of the following:
 
 
March 31, 2015
 
December 31, 2014
Raw material
$
20,912

 
$
23,006

Work in process
5,126

 
3,546

Finished goods
11,622

 
10,381

Total
$
37,660

 
$
36,933

 
Note 7:
Property and Equipment

Property and equipment consisted of the following:
 
 
March 31, 2015
 
December 31, 2014
Machinery and equipment
$
90,630

 
$
90,744

Land, building and building improvements
70,231

 
71,415

Molds
33,349

 
33,166

Computer equipment and software
23,488

 
23,228

Furniture and fixtures
3,450

 
3,571

Construction in progress
2,878

 
2,590

Total property and equipment, cost
224,026

 
224,714

Accumulated depreciation
(141,738
)
 
(138,623
)
Net property and equipment
$
82,288

 
$
86,091


Note 8:
Net Income Per Share
 
Net income per share is computed by dividing net income by the weighted average number of common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average number of common shares outstanding plus dilutive securities. Dilutive securities are outstanding common stock options and restricted stock units(excluding stock options with an exercise price in excess of the average market value for the period), less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive because their exercise price exceeded the average market price of the common stock for the period approximated 76,000 for the three months ended March 31, 2015 and 237,000 for the three months ended March 31, 2014.
 
The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted.
 
 
Three months ended March 31,
 
2015
 
2014
Net income
$
9,686

 
$
6,657

Weighted average number of common shares outstanding (for basic calculation)
15,693

 
15,097

Dilutive securities
541

 
298

Weighted average common and common equivalent shares outstanding (for diluted calculation)
16,234

 
15,395

EPS — basic
$
0.62

 
$
0.44

EPS — diluted
$
0.60

 
$
0.43

 

9

Note 9:
Major Customer
    
We had revenues equal to 10% or more of total revenues from one customer, Hospira, Inc. Such revenues were 36% and 35% of total revenue for the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015 and December 31, 2014, we had accounts receivable from Hospira of 25% and 27% of consolidated accounts receivable, respectively.
 
Note 10:
Income Taxes
 
Income taxes were accrued at an estimated effective tax rate of 16% and 34% in the first quarters of 2015 and 2014, respectively. The effective tax rate differs from that computed at the federal statutory rate of 35% principally because of the effect of foreign and state income taxes, tax credits, deductions for domestic production activities and material discrete tax benefits related to the impact of changes in estimates of tax reserves as a result of the favorable conclusion of recent federal and state examinations.

Note 11:
Restructuring

In 2014, we reorganized our selling and corporate infrastructure, resulting in a reduction in workforce of 69 employees. We have $0.6 million accrued for the restructuring charges as of March 31, 2015.

Note 12:
Treasury Stock

In July 2010, our Board of Directors approved a common stock purchase plan to purchase up to $40.0 million of our common stock. This plan has no expiration date and we have $22.5 million remaining on this purchase plan. We expect to use the treasury stock to issue shares for stock option exercises, restricted stock grants and employee stock purchase plan stock purchases.

In the first quarter of 2015, we withheld 16,401 shares of our common stock from employee vested restricted stock units in consideration for $1.4 million in payments for the employee's share award income tax withholding obligations.

 
Note 13:
Commitments and Contingencies

From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business.  Our management does not believe that the resolution of the other legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations.
 
In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products.  There is no maximum limit on the indemnification that may be required under these agreements.  Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification.


10

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
Business Overview
    
We are a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications.  Our product line include needlefree connection devices, custom infusion sets, closed system transfer devices ("CSTD") for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and innovative hemodynamic monitoring systems.

Our products are used in acute care hospitals and ambulatory clinics in more than 60 countries throughout the world. We categorize our products into three main market segments: Infusion Therapy, Critical Care and Oncology. In the prior period, we included Lopez enteral valve under Infusion Therapy. The Lopez Valve is now included under Critical Care for all periods presented. Our primary products include:

Infusion Therapy
•Needlefree connector products
◦MicroClave and MicroClave Clear
◦Anti-Microbial MicroClave
◦Neutron
◦NanoClave
◦Clave
•Custom infusion sets
•Tego needlefree hemodialysis connector

Critical Care
•Hemodynamic monitoring systems
◦Transpac disposable pressure transducers
◦Safeset closed needlefree blood conservation systems
◦Custom monitoring systems
•Catheters
◦Advanced sensor catheters
◦Pulmonary artery thermodilution catheters
◦Central venous oximetry catheters
◦Multi-lumen central venous catheters
•Custom angiography and interventional radiology kits
•Lopez enteral valve
    
Oncology
•ChemoLock CSTD and components
•ChemoClave CSTD and components
•Diana hazardous drug compounding system

Our largest customer is Hospira.  Hospira accounted for 36%, 36% and 39% of our worldwide revenues in the first quarter of 2015 and each of the years ended 2014 and 2013, respectively. Our relationship with Hospira has been and will continue to be important for our growth.  Hospira has a significant share of the I.V. set market in the U.S. and provides us access to that market. We expect revenues from infusion therapy sales and new products to Hospira to remain a significant percentage of our revenues.

Revenues for the first quarter of 2015 and the years ended 2014 and 2013 were $81.5 million, $309.3 million and $313.7 million, respectively. We currently sell our products to medical product manufacturers, independent distributors and through direct sales to the end user. Most of our independent distributors handle the full line of our products.  We sell our infusion administration and oncology products under two agreements with Hospira.  Under a 1995 agreement, Hospira purchases Clave products, principally bulk, non-sterile connectors and oncology products.  Under a 2001 agreement, we sell custom infusion sets to Hospira under a program referred to as SetSource.  Our 1995 and 2001 agreements with Hospira provide Hospira with conditional exclusive and nonexclusive rights to distribute all existing ICU Medical products worldwide with terms that extend through most of 2018. 

We believe that as healthcare providers continue to either consolidate or join major buying organizations, the success of our products will depend, in part, on our ability, either independently or through strategic relationships such as our Hospira

11

relationship, to secure long-term contracts with large healthcare providers and major buying organizations.  As a result of this marketing and distribution strategy we derive most of our revenues from a relatively small number of distributors and manufacturers.  The loss of a strategic relationship with a customer or a decline in demand for a manufacturing customer’s products could have a material adverse effect on our operating results.
 
We believe that achievement of our growth objectives worldwide will require increased efforts by us in sales and marketing and product development; however, there is no assurance that we will be successful in implementing our growth strategy. Product development or acquisition efforts may not succeed, and even if we do develop or acquire additional products, there is no assurance that we will achieve profitable sales of such products.  An adverse change in our relationship with Hospira, or a deterioration of Hospira’s position in the market, could have an adverse effect on us. We believe the April 2015 ruling that we had a breach of contract with Hospira will not have a significant impact on our earnings going forward.  Increased expenditures for sales and marketing and product acquisition and development may not yield desired results when expected, or at all.  While we have taken steps to control these risks, there are certain risks that may be outside of our control, and there is no assurance that steps we have taken will succeed.

The following table sets forth, for the periods indicated, total revenues by product line as a percentage of total revenues.  
 
 
 
Three months ended March 31,
 
Fiscal year ended
Product line
 
2015
 
2014
 
2014
 
2013
Infusion therapy
 
72
%
 
69
%
 
70
%
 
71
%
Oncology
 
11
%
 
12
%
 
12
%
 
12
%
Critical care
 
17
%
 
19
%
 
18
%
 
17
%
Other
 
—
%
 
—
%
 
—
%
 
—
%
 
 
100
%
 
100
%
 
100
%
 
100
%
   
Seasonality/Quarterly Results
 
The healthcare business in the United States ("U.S.") is subject to quarterly fluctuations due to frequency of illness during the seasons, elective procedures, and over the last few years, the economy. In Europe, the healthcare business generally slows down in the summer months due to vacations resulting in fewer elective surgeries.  In addition, we can experience fluctuations in net sales as a result of variations in the ordering patterns of our largest customers, which may be driven more by production scheduling and their inventory levels, and less by seasonality.  Our expenses often do not fluctuate in the same manner as net sales, which may cause fluctuations in operating income that are disproportionate to fluctuations in our revenue.

12

Quarter-to-Quarter Comparisons

We present income statement data in Part I, Item 1 - Financial Statements. The following table shows, for the quarters ended March 31, 2015 and 2014 and the year ended December 31, 2014, the percentages of each income statement caption in relation to total revenues.
 
 
 
Percentage of revenues
 
 
Three months ended March 31,
 
Fiscal year
 
 
2015
 
2014
 
2014
Total revenues
 
100
%
 
100
%
 
100
%
Gross margin
 
52
%
 
49
%
 
49
%
Selling, general and administrative expenses
 
25
%
 
31
%
 
29
%
Research and development expenses
 
5
%
 
5
%
 
6
%
Restructuring and transaction expense
 
—
%
 
—
%
 
1
%
Legal settlement
 
9
%
 
—
%
 
—
%
Total operating expenses
 
39
%
 
36
%
 
36
%
Income from operations
 
13
%
 
13
%
 
13
%
Other income
 
1
%
 
—
%
 
—
%
Income before income taxes
 
14
%
 
13
%
 
13
%
Income taxes
 
2
%
 
4
%
 
4
%
Net income
 
12
%
 
9
%
 
9
%

    
Quarter Ended March 31, 2015 Compared to the Quarter Ended March 31, 2014
 
A portion of our sales is conducted in currencies other than the U.S. dollar, particularly the Euro. In the first quarter of 2015, approximately 14% of our total revenue was denominated in the Euro and translated to the U.S. dollar. Significant fluctuations in foreign currency exchange rates, particularly the Euro, impact the comparability of our total revenues. In addition to comparing changes in revenue on a U.S. GAAP basis, we also compare the changes in revenue from one period to another using constant currency. We provide constant currency information to enhance the visibility of underlying business trends, excluding the effects of changes in foreign currency translation rates. To calculate our constant currency results, we apply the average exchange rate for revenues from the prior year to the current year results. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Revenues were $81.5 million in the first quarter of 2015 and $73.2 million in the first quarter of 2014. On a constant currency basis, revenues would have been $83.9 million in the first quarter of 2015, an increase of $10.7 million, or 15%, from the first quarter of 2014.
 
Infusion Therapy:   Net infusion therapy sales were $58.5 million in the first quarter of 2015, an increase of $8.5 million, or 17%, from the first quarter of 2014. On a constant currency basis, net infusion therapy sales would have been $59.9 million in the first quarter of 2015, an increase of $9.9 million, or 20%, from the first quarter of 2014. Domestic infusion therapy sales were $43.5 million in the first quarter of 2015, an increase of $9.1 million, or 26%, from the first quarter of 2014. The increase in domestic infusion therapy was from $6.1 million in higher sales to Hospira and $2.9 million in higher direct domestic sales. International infusion therapy sales were $15.0 million in the first quarter of 2015, a decrease of $0.6 million, or 4%, from the first quarter of 2014. The decrease in international infusion therapy sales was due to the decline in the exchange rate of the Euro to the U.S. dollar. On a constant currency basis, international infusion therapy sales would have increased $0.8 million in the first quarter of 2015, compared to the first quarter of 2014.

Oncology: Net oncology sales were $8.9 million in the first quarter of 2015, a decrease of $0.1 million, or 1%, from the first quarter of 2014. On a constant currency basis, net oncology sales would have been $9.7 million in the first quarter of 2015, an increase of $0.7 million, or 8%, from the first quarter of 2014. Domestic oncology sales were $3.9 million in the first quarter of 2015, a decrease of $0.1 million, or 1%, from the first quarter of 2014. The decrease in domestic oncology sales is due to $0.5 million in lower sales to Hospira due to lower unit sales, partially offset by an increase in direct domestic oncology

13

sales of $0.4 million due to higher unit sales. International oncology sales were $5.0 million in both the first quarter of 2015 and the first quarter of 2014. On a constant currency basis, international infusion therapy sales would have increased $0.8 million in the first quarter of 2015, compared to the first quarter of 2014.
 
Critical Care: Net critical care sales were $13.7 million in the first quarter of 2015, a decrease of $0.3 million, or 2%, from the first quarter of 2014. On a constant currency basis, net critical care sales would have been $13.9 million in both the first quarter of 2015 and the first quarter of 2014. Domestic critical care sales were $10.1 million in both the first quarter of 2015 and the first quarter of 2014. International critical care sales were $3.6 million in the first quarter of 2015, a decrease of $0.3 million, or 7%, from the first quarter of 2014. The decrease in international critical care sales was due to the decline in the exchange rate of the Euro to the U.S. dollar. On a constant currency basis, international critical care sales would have been comparable in the first quarter of 2015 to the first quarter of 2014.

Gross margins for the first quarters of 2015 and 2014 were 52% and 49%, respectively. The increase in gross margin was primarily due to favorable customer and product mix and lower operational expenses.

Selling, general and administrative expenses (“SG&A”) were $20.2 million, or 25% of revenues, in the first quarter of 2015, compared with $22.5 million, or 31%, of revenues in first quarter of 2014.  The decrease in SG&A expenses is primarily from $3.0 million in lower sales and marketing compensation and benefits and travel expenses, partially offset by $0.8 million in higher stock compensation expense. The lower sales and marketing expenses are primarily due to the restructuring of the U.S. sales organization in the third quarter of 2014 and the decline in the average exchange rate of the Euro to the U.S. dollar.
 
Research and development expenses (“R&D”) were $4.3 million, or 5% of revenue, in the first quarter of 2015 compared to $3.6 million, or 5%, of revenue in the first quarter of 2014.  The increase in R&D expenses was primarily from increased R&D compensation and benefits expenses from an increase in R&D employees and increased R&D project expenses.

Legal settlement charges were $7.1 million, or 9% of revenues, in the first quarter of 2015. On April 2, 2015, an arbitrator ruled on a breach of contract claim between us and Hospira, awarding Hospira $8.2 million Canadian dollars ($6.5 million U.S. dollars). The arbitrator also ruled that we shall pay 75% of Hospira's legal fees and expenses, which we estimated to be $0.8 million Canadian dollars ($0.6 million U.S. dollars.

Other income was $0.5 million in the first quarter of 2015 and $0.2 million in the first quarter of 2014. 

Income taxes were accrued at an estimated effective tax rate of 16% in the first quarter of 2015 and 34% in the first quarter of 2014.  The rate differed from the statutory corporate rate of 35% principally because of the effect of foreign and state income taxes, tax credits, deductions for domestic production activities, discrete tax items related to the conclusion of federal tax examinations and changes in estimates of tax reserves. 

Liquidity and Capital Resources
 
During the first quarter of 2015, our cash, cash equivalents and investment securities increased by $8.0 million from $346.8 million at December 31, 2014 to $354.8 million at March 31, 2015.
 
Operating Activities: Our cash provided by operating activities is subject to fluctuations, principally from changes in net income, accounts receivable, inventories and the timing of tax payments.
 
Our cash provided by operations was $13.3 million in the first quarter of 2015. Net income plus adjustments for non-cash net expenses contributed $18.1 million to cash provided by operations, which was partially offset by a $4.8 million decrease in cash provided by operating assets and liabilities. The $5.0 million increase in accounts receivable was the largest change in operating assets and liabilities. Cash provided by the change in accounts receivable is primarily due to higher revenue in the first quarter of 2015 compared to the fourth quarter of 2014.

Investing Activities:  Our cash provided by investing activities was $20.0 million in the first quarter of 2015, which was primarily comprised of net investment sales of $22.6 million, partially offset by $2.4 million in capital purchases.
 
While we can provide no assurances, we estimate that our capital expenditures in 2015 will approximate $12.0 million to $14.0 million. We anticipate making additional investments in molds, machinery and equipment in our manufacturing operations in the U.S. and Mexico to support new and existing products and in IT to benefit world-wide operations. We expect

14

to use our cash and investments to fund our capital purchases. These planned amounts of spending are estimates and actual spending may substantially differ from these amounts.
 
Financing Activities:  Our cash provided by financing activities was $7.4 million in the first quarter of 2015. Cash and tax benefits provided by the exercise of stock options and shares purchased by our employees under the employee stock purchase plan was $8.9 million in the first quarter of 2015. In the first quarter of 2015, we withheld 16,401 shares of our common stock from vested restricted stock units as consideration for $1.4 million in payments for the employee's share award tax withholding obligations.

In July 2010, our Board of Directors approved a share purchase plan to purchase up to $40.0 million of our common stock.  To date, we purchased $17.5 million of our common stock pursuant to this plan, leaving a balance of $22.5 million available for future purchases. This plan has no expiration date. We may purchase additional shares in future quarters and expect we would use our cash and investments to fund the share purchases.
 
We have a substantial cash and investment security position generated from profitable operations and stock sales, principally from the exercise of employee stock options.  We maintain this position to fund our growth, meet increasing working capital requirements, fund capital expenditures, and to take advantage of acquisition opportunities that may arise.  Our primary investment goal is capital preservation.

As of March 31, 2015, we have $24.6 million of cash and cash equivalents held by our foreign subsidiaries. If these funds were needed for our operations in the U.S., we would be required to accrue and pay U.S. taxes to repatriates these funds. However, we expect to permanently reinvest these funds outside of the U.S. and, based on our current plans, we do not presently anticipate a need to repatriate them to fund our U.S. operations.
 
We believe that our existing cash, cash equivalents and investment securities along with funds expected to be generated from future operations will provide us with sufficient funds to finance our current operations for the next twelve months.  In the event that we experience illiquidity in our investment securities, downturns or cyclical fluctuations in our business that are more severe or longer than anticipated or if we fail to achieve anticipated revenue and expense levels, we may need to obtain or seek alternative sources of capital or financing, and we can provide no assurances that the terms of such capital or financing will be available to us on favorable terms, if at all.

Off Balance Sheet Arrangements
 
In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products.  There is no maximum limit on the indemnification that may be required under these agreements.  Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification.
 

Contractual Obligations
 
We have contractual obligations, at March 31, 2015, of approximately the amounts set forth in the table below. These amounts exclude inventory related purchase orders for goods and services for current delivery. The majority of our inventory purchase orders are blanket purchase orders that represent an estimated forecast of goods and services. We do not have a commitment liability on the blanket purchase orders. Since we do not have the ability to separate out blanket purchase orders from non-blanket purchase orders for inventory related goods and services for current delivery, amounts related to such purchase orders are excluded from the table below.  We have excluded from the table below pursuant to ASC 740-10-25 (formerly FIN 48), an interpretation of ASC 740-10 (formerly SFAS 109), a non-current income tax liability of $1.2 million due to the high degree of uncertainty regarding the timing of future cash outflows associated with the liabilities.
 
 
 
(in thousands)
 
 
Contractual Obligations
 
Total
 
2015
 
2016
 
2017
 
2018
Operating leases
 
$
363

 
$
222

 
$
96

 
$
35

 
10

Service agreements
 
1,281

 
464

 
613

 
204

 
—

Purchase obligations
 
7,316

 
7,316

 
—

 
—

 
—

Other contractual obligations
 
$
26

 
$
10

 
$
13

 
$
3

 
—

 
 
$
8,986

 
$
8,012

 
$
722

 
$
242

 
10


15

 
Critical Accounting Policies
 
In our Annual Report on Form 10-K for the year ended December 31, 2014, we identified the critical accounting policies which affect our more significant estimates and assumptions used in preparing our consolidated financial statements. We have not changed these policies from those previously disclosed in our Annual Report.
 
New Accounting Pronouncements
 
See Note 3 to Part I, Item 1.  Financial Statements.

Forward Looking Statements
 
Various portions of this Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis of Financial Condition and Results of Operations, describe trends in our business and finances that we perceive and state some of our expectations and beliefs about our future. These statements about the future are “forward looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we identify them by using words such as "anticipate," "believe," "expect," "estimate," "intend," "plan," "will," "continue," "could," "may," and by similar expressions and statements about aims, goals and plans. The forward looking statements are based on the best information currently available to us and assumptions that we believe are reasonable, but we do not intend the statements to be representations as to future results. They include, without limitation, statements about:

•
future growth; future operating results and various elements of operating results, including future expenditures and effects with respect to sales and marketing and product development and acquisition efforts; future sales and unit volumes of products; expected increases and decreases in sales; deferred revenue; accruals for restructuring charges, future license, royalty and revenue share income; production costs; gross margins; litigation expense; future SG&A and R&D expenses; manufacturing expenses; future costs of expanding our business; income; losses; cash flow; amortization; source of funds for capital purchases and operations; future tax rates; alternative sources of capital or financing; changes in working capital items such as receivables and inventory; selling prices; and income taxes;

•
factors affecting operating results, such as shipments to specific customers; reduced dependence on current proprietary products; loss of a strategic relationship; change in demand; domestic and international sales; expansion in international markets, selling prices; future increases or decreases in sales of certain products and in certain markets and distribution channels; maintaining strategic relationships and securing long-term and multi-product contracts with large healthcare providers and major buying organizations; increases in systems capabilities; introduction, development and sales of new products; benefits of our products over competing systems; qualification of our new products for the expedited Section 510(k) clearance procedure; possibility of lengthier clearance process for new products; planned increases in marketing; warranty claims; rebates; product returns; bad debt expense; amortization expense; inventory requirements; lives of property and equipment; manufacturing efficiencies and cost savings; unit manufacturing costs; establishment or expansion of production facilities inside or outside of the United States; planned new orders for semi-automated or fully automated assembly machines for new products; adequacy of production capacity; results of R&D; our plans to repurchase shares of our common stock; asset impairment losses; relocation of manufacturing facilities and personnel; effect of expansion of manufacturing facilities on production efficiencies and resolution of production inefficiencies; the effect of costs to customers and delivery times; business seasonality and fluctuations in quarterly results; customer ordering patterns and the effects of new accounting pronouncements; and

•
new or extended contracts with manufacturers and buying organizations; dependence on a small number of customers; loss of larger distributors and the ability to locate other distributors; future sales to and revenues from Hospira and the importance of Hospira to our growth; effect of the current relationship with Hospira, including its effect on future revenues and our positioning with respect to new product introductions and market share; growth of our Clave products in future years; design features of Clave products; the outcome of our strategic initiatives; regulatory approvals and compliance; outcome of litigation; patent protection and intellectual property landscape; patent infringement claims and the impact of newly issued patents on other medical devices; competitive and market factors, including continuing development of competing products by other manufacturers; improved production processes and higher volume production; innovation requirements; consolidation of the healthcare provider market and downward pressure on selling prices;

16

distribution or financial capabilities of competitors; healthcare reform legislation; use of treasury stock; working capital requirements; liquidity and realizable value of our investment securities; future investment alternatives; foreign currency denominated financial instruments; foreign exchange risk; commodity price risk; our expectations regarding liquidity and capital resources over the next twelve months; capital expenditures; our planned reinvestment of cash and cash equivalents held by our foreign subsidiaries; plans to convert existing space; acquisitions of other businesses or product lines, indemnification liabilities and contractual liabilities.

 Forward-looking statements involve certain risks and uncertainties, which may cause actual results to differ materially from those discussed in each such statement.  First, one should consider the factors and risks described in the statements themselves or otherwise discussed herein. Those factors are uncertain, and if one or more of them turn out differently than we currently expect, our operating results may differ materially from our current expectations.
 
Second, investors should read the forward looking statements in conjunction with the Risk Factors discussed in Part I, Item 1A of our Annual Report on Form 10-K with the SEC for the year ended December 31, 2014 and our other reports and registration statements filed with the SEC.  Also, actual future operating results are subject to other important factors and risks that we cannot predict or control, including without limitation, the following:

•
general economic and business conditions, both in the U.S. and internationally;

•
unexpected changes in our arrangements with Hospira or our other large customers;

•outcome of litigation;

•fluctuations in foreign exchange rates and other risks of doing business internationally;

•increases in labor costs or competition for skilled workers;

•increases in costs or availability of the raw materials need to manufacture our products;

•the effect of price and safety considerations on the healthcare industry;

•competitive factors, such as product innovation, new technologies, marketing and distribution strength and price erosion;

•the successful development and marketing of new products;

•unanticipated market shifts and trends;

•the impact of legislation affecting government reimbursement of healthcare costs;

•
changes by our major customers and independent distributors in their strategies that might affect their efforts to market our products;

•the effects of additional governmental regulations;

•unanticipated production problems; and

•the availability of patent protection and the cost of enforcing and of defending patent claims.

The forward-looking statements in this report are subject to additional risks and uncertainties, including those detailed from time to time in our other filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof and, except as required by law, we undertake no obligation to update or revise any of them, whether as a result of new information, future events or otherwise.

Item 3.
Quantitative and Qualitative Disclosures about Market Risk
 
Financial Market Risk


17

We had a portfolio of federal tax-exempt state and municipal government bonds, corporate bonds, commercial paper and certificates of deposit of $46.3 million as of March 31, 2015.  The securities are all “investment grade”, comprised of $13.4 million of pre-refunded municipal securities, $0.4 million of non-pre-refunded municipal securities, $24.5 million in corporate bonds, $4.5 million in commercial paper and $3.5 million of certificates of deposit.  The pre-refunded municipal securities are fully escrowed by U.S. government Treasury bills with low market risk.
 
Our future earnings are subject to potential increase or decrease because of changes in short-term interest rates. Generally, each one-percentage point change in the discount rate will cause our overall yield to change by two-thirds to three-quarters of a percentage point, depending upon the relative mix of federal-tax-exempt securities in our portfolio and market conditions specific to the securities in which we invest.  Two-thirds to three-quarters of a percentage point change in our earnings on investment securities would create a change of approximately $0.3 million to investment income based on the investment securities balance at March 31, 2015.
 
Foreign Exchange Risk    

We have foreign currency exchange risk related to foreign-denominated cash, short-term investments, accounts
receivable and accounts payable. In our European operations, our net Euro asset position at March 31, 2015 was
approximately €21.7 million. We also have approximately €56.7 million in Euro denominated cash and investment accounts
held by our corporate entity. A 10% change in the conversion of the Euro to the U.S. dollar for our cash and investments,
accounts receivable, accounts payable and accrued liabilities from the March 31, 2015 spot rate would impact our
consolidated amounts on these balance sheet items by approximately $8.5 million, or 2.3% of these net assets. We expect that in the future, with the growth of our European distribution operation, net Euro denominated instruments will continue to
increase. We currently do not hedge our foreign currency exposures.

Sales from the U.S. to foreign distributors are denominated in U.S. dollars. We have manufacturing, sales and distribution facilities in several countries and we conduct business transactions denominated in various foreign currencies, although principally the Euro and Mexican Peso. A 10% change in the conversion of the Mexican Peso to the U.S. dollar from the average exchange rate we experienced in 2014 and our manufacturing spending from 2014 would have impacted 2014 cost of goods sold by approximately $2.4 million.

Commodity Risk

Our exposure to commodity price changes relates primarily to certain manufacturing operations that use resin. We manage our exposure to changes in those prices through our procurement and supply chain management practices and the effect of price changes has not been material to date.  Based on our average price for resin in fiscal year 2014, a 10% increase to the price of resin would have resulted in approximately a $1.2 million change in material cost.

Item 4.
Controls and Procedures
 
Disclosure Controls and Procedures
 
Our principal executive officer and principal financial officer have concluded, based on their evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this Report, that our disclosure controls and procedures are effective to ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure and that such information is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.
 
There was no change in our internal control over financial reporting during the quarter ended March 31, 2015 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.



PART II - OTHER INFORMATION

Item 1.
Legal Proceedings
 
We are from time to time involved in various other legal proceedings, either as a defendant or plaintiff, most of which are routine litigation in the normal course of business. We believe that the resolution of the legal proceedings in which we are involved will not have a material adverse effect on our financial position or results of operations.


18

Item 1A.
Risk Factors
 
In evaluating an investment in our common stock, investors should consider carefully, among other things, the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2014, as well as the information contained in this Quarterly Report and our other reports and registration statements filed with the SEC.  There have been no material changes in the risk factors as previously disclosed under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K with the SEC for the year ended December 31, 2014.


Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
 
In July 2010, our Board of Directors approved a common stock purchase plan to purchase $40.0 million of our common stock.  This plan has no expiration date. We are not obligated to make any purchases under our stock purchase program. Subject to applicable state and federal corporate and securities laws, purchases under a stock purchase program may be made at such times and in such amounts as we deem appropriate. Purchases made under our stock purchase program can be discontinued at any time we feel additional purchases are not warranted.

The following is a summary of our stock repurchasing activity during the first quarter of 2015:

Period
 
Shares
purchased
 
Average
price paid
per share
 
Shares
purchased as
part of a
publicly
announced
program
 
Approximate
dollar value that
may yet be
purchased under
the program
01/01/2015 — 01/31/2015
 
—

 
$
—

 
—

 
$
22,522,000

02/01/2015 — 02/28/2015
 
—

 
—

 
—

 
22,522,000

03/01/2015 — 03/31/2015
 
—

 
—

 
—

 
22,522,000

First quarter of 2015 total
 
—

 
$
—

 
—

 
$
22,522,000


Item 6. Exhibits
 
 
 
Exhibit 31.1
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
Exhibit 31.2
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
Exhibit 32.1
 
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
Exhibit 101.INS
 
XBRL Instance Document
 
 
 
Exhibit 101.SCH
 
XBRL Taxonomy Extension Schema Document
 
 
 
Exhibit 101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
Exhibit 101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
Exhibit 101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
Exhibit 101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document


19


Signature
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
ICU Medical, Inc.
 
(Registrant)
 
 
 
 
 
/s/ Scott E. Lamb
Date:
May 6, 2015
Scott E. Lamb
 
 
Chief Financial Officer
 
 
(Principal Financial Officer)
 
 


20

xhibit Index
 
 
 
 
Exhibit 31.1
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
Exhibit 31.2
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
Exhibit 32.1
 
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
Exhibit 101.INS
 
XBRL Instance Document
 
 
 
Exhibit 101.SCH
 
XBRL Taxonomy Extension Schema Document
 
 
 
Exhibit 101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
Exhibit 101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
Exhibit 101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
Exhibit 101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document


21